Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.4 USD | -4.09% | -3.57% | 0.00% |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales | - | - | - |
EBITDA | - | - | - |
EBIT 1 | -0.1381 | -0.8541 | -3.942 |
Operating Margin | - | - | - |
Earnings before Tax (EBT) 1 | -0.1381 | -0.8541 | -13.07 |
Net income 1 | -0.1381 | -0.8541 | -13.07 |
Net margin | - | - | - |
EPS | - | -0.0318 | -0.4787 |
Free Cash Flow | - | - | -1.963 |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 8/14/23 | 8/14/23 | 3/29/24 |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | 0.12 | 0.58 | 0.63 |
Net Cash position 1 | - | - | - |
Leverage (Debt/EBITDA) | - | - | - |
Free Cash Flow | - | - | -1.96 |
ROE (net income / shareholders' equity) | - | 159% | -1,045% |
ROA (Net income/ Total Assets) | - | - | -102% |
Assets 1 | - | - | 12.79 |
Book Value Per Share | - | -0.0300 | 0.1200 |
Cash Flow per Share | - | 0 | 0 |
Capex | - | - | - |
Capex / Sales | - | - | - |
Announcement Date | 8/14/23 | 8/14/23 | 3/29/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
0.00% | 160M | |
+48.39% | 779B | |
-6.13% | 354B | |
+20.61% | 333B | |
+10.00% | 301B | |
+19.40% | 249B | |
-1.39% | 216B | |
+11.90% | 214B | |
+5.80% | 163B | |
-2.50% | 159B |
- Stock Market
- Equities
- TELO Stock
- Financials Telomir Pharmaceuticals, Inc.